Home   »   Media   »   Newsletter Q4 2018

Newsletter Q4 2018

The field of Alzheimer’s research remains frustratingly unchanged, characterized by frequent claims of research breakthroughs, followed by predictable clinical failures.

Watch more

  • Newsletter Q1 2019
  • Telocyte focuses on Alzheimer’s disease. Once we have engaged in our phase 1 FDA trial, currently slated for 2020, we plan to engage with other age-related diseases...

  • PLOS Genetics
  • This article in PLOS Genetics shows that telomerase activation using AAV9 vectors and telomerase gene is not necessarily associated with increased cancer risk and supports the safety of AAV-mediated telomerase activation as an innovative treatment for age-related disease.

  • Phacilitate Investment Report
  • This industry report, citing Telocyte, notes that “there is little doubt of the role gene therapies will play in the future of medicine… The advanced therapy sector is a rapidly growing industry which offers substantial opportunities for return on investment (ROI)."